Population distribution of methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C risk alleles for methotrexate toxicity in Israel

Rheumatology International

Volumn 33, Issue 4, 2013, Pages 1001-1004

  Efrati, Edna ^a   Elkin, Hela ^a   Nahum, Sagi ^a   Krivoy, Norberto ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Genotype; Methotrexate; MTHFR; Pharmacogenetics; Toxicity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ALLELE; ARAB; ARTICLE; ENZYME ACTIVITY; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INCIDENCE; ISRAEL; JEW; METHYLENETETRAHYDROFOLATE REDUCTASE GENE; MOSLEM; POPULATION DISTRIBUTION; PRIORITY JOURNAL; RELIGIOUS GROUP; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; CAUCASIAN; DEMOGRAPHY; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; PHARMACOGENETICS;

ADULT; ALLELES; ARABS; DEMOGRAPHY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ISRAEL; JEWS; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84886621802     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2494-1     Document Type: Article

References (15)

1. Hider SL, Bruce IN, Thomson W (2007) The pharmacogenetics of methotrexate. Rheumatology (Oxford, England) 46(10): 1520-1524
2. Wessels JA, de Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YP, Allaart CF, Kerstens PJ, van Zeben D, Breedveld FC, Dijkmans BA, Huizinga TW, Guchelaar HJ (2006) Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 54(4): 1087-1095
3. Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y, Akama H, Kitamura Y, Kamatani N (2002) Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12(3): 183-190
4. Ongaro A, De Mattei M, Della Porta MG, Rigolin G, Ambrosio C, Di Raimondo F, Pellati A, Masieri FF, Caruso A, Catozzi L, Gemmati D (2009) Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica 94(10): 1391-1398
5. Kremer JM (2006) Methotrexate pharmacogenomics. Ann Rheum Dis 65(9): 1121-1123
6. Hughes LB, Beasley TM, Patel H, Tiwari HK, Morgan SL, Baggott JE, Saag KG, McNicholl J, Moreland LW, Alarcon GS, Bridges SL Jr (2006) Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 65(9): 1213-1218
7. Rady PL, Tyring SK, Hudnall SD, Vargas T, Kellner LH, Nitowsky H, Matalon RK (1999) Methylenetetrahydrofolate reductase (MTHFR): the incidence of mutations C677T and A1298C in the Ashkenazi Jewish population. Am J Med Genet 86(4): 380-384
8. Sinthuwiwat T, Poowasanpetch P, Wongngamrungroj A, Promso S, Auewarakul C, Mooney S, Tocharoentanaphol C (2008) Highresolution melting curve analysis for genotyping of common SNP in MTHFR gene using fixed-cell suspension. Mol Cell Probes 22(5-6): 329-332
9. Norambuena PA, Copeland JA, Krenkova P, Stambergova A, Macek M Jr (2009) Diagnostic method validation: high-resolution melting (HRM) of small amplicons genotyping for the most common variants in the MTHFR gene. Clin Biochem 42(12): 1308-1316
10. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64(3): 169-172
11. Weisman MH, Furst DE, Park GS, Kremer JM, Smith KM, Wallace DJ, Caldwell JR, Dervieux T (2006) Risk genotypes in folate-dependent enzymes and their association with methotrexate- related side effects in rheumatoid arthritis. Arthritis Rheum 54(2): 607-612
12. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, Kremer J (2004) Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 50(9): 2766-2774
13. van Ede AE, Laan RF, Blom HJ, Huizinga TW, Haagsma CJ, Giesendorf BA, de Boo TM, van de Putte LB (2001) The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 44(11): 2525-2530
14. Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J, Ariail KS, Keener CL, Li S, Liu H, Farin FM, Potter JD (2001) Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98(1): 231-234
15. Ranganathan P, Eisen S, Yokoyama WM, McLeod HL (2003) Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis 62(1): 4-9